Form D · Biotechnology

Rezo Therapeutics, Inc.

San Francisco, CA · CIK 0001956559

Offering snapshot reported Aug 18, 2025 · SEC filing

Reported sold
$68.1M
Offering amount: $80.1M
Investors reported
21
Form D · investor count
Minimum accepted
Not reported
Reported outside-investor minimum
First sale
Jul 21, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 18, 2025Amendment$68,066,039No comparison21SEC filing
Dec 18, 2023Amendment$46,348,088$31,731,850vs Dec 1, 202220SEC filing
Dec 1, 2022Initial$14,616,238No comparison20SEC filing

Offering details

Securities
Not reported
Exemptions
Not reported
Duration over one year
Not reported
Business combination
Not reported
Sales commissions
$0
Finders' fees
$0
Form D file number
021-466228
This filing covers the sale and purchase of Series A Preferred Stock, and the Common Stock issuable upon conversion thereof.

Source: Form D, filed Aug 18, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Vineeta Agarwala Director
Tiba Aynechi Director
Sourav Bandyopadhyay Executive, Promoter
Norbert Bischofberger Director
Jennifer Chang Executive
Simeon George Director
Derek Hicks Director, Executive
Nevan Krogan Director, Executive
Nadir Mahmood Director, Executive, Promoter
George Scangos Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
455 Mission Bay Boulevard South Suite 525
San Francisco, CA, 94158